Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus/MMF +/- Sirolimus for GVHD Prevention
NCT00105001Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2004
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of sirolimus in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Started Nov 2004; status: completed.
02
Drugs
sirolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00105001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00105001.